This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.89% per year. These returns cover a period from January 1, 1988 through March 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
by Zacks Equity Research
Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.
BMYPositive Net Change FOLDPositive Net Change CYTKPositive Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's Why Summit Therapeutics Stock Soared 15% on Friday
by Zacks Equity Research
The surge in SMMT's share price comes after some established investment firms maintain their positive outlook on the company, citing optimism around its lead pipeline drug.
MRKNegative Net Change SMMTPositive Net Change TILPositive Net Change BNTXPositive Net Change
biotechs medical pharmaceuticals
Bayer Obtains Full FDA Approval for Oncology Drug Vitrakvi
by Zacks Equity Research
The FDA converts its accelerated approval to full approval for BAYRY's oncology drug, Vitrakvi, on positive data from confirmatory studies.
BAYRYPositive Net Change FOLDPositive Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
by Zacks Equity Research
The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.
DVAXPositive Net Change BAYRYPositive Net Change ADMAPositive Net Change KROSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
by Zacks Equity Research
The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.
JAZZPositive Net Change ARCTPositive Net Change ADMAPositive Net Change KRYSPositive Net Change
biotechs
NVAX Stock Tanks as HHS Secretary Raises Concern Over COVID-19 Jab
by Zacks Equity Research
The decline in Novavax stock follows the HHS Secretary's concerns regarding the efficacy of its protein-based COVID-19 vaccine in a recent interview.
PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
by Zacks Equity Research
The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.
PFEPositive Net Change ANIPPositive Net Change ETNBPositive Net Change PCVXPositive Net Change
biotechs medical pharmaceuticals vaccines
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why
by Zacks Equity Research
Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line.
JAZZPositive Net Change TGTXPositive Net Change KRYSPositive Net Change DTILPositive Net Change
biotechs
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose
by Zacks Equity Research
Phio Pharmaceuticals stock rallies as safety committee gives green light to advance skin cancer candidate to next dose concentration in phase I study.
DVAXPositive Net Change BAYRYPositive Net Change ADMAPositive Net Change PHIOPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up
by Zacks Equity Research
Anixa Biosciences stock jumps 13% on new patent grant for its breast cancer vaccine technology in the United States.
DVAXPositive Net Change BAYRYPositive Net Change ADMAPositive Net Change ANIXPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study
by Zacks Equity Research
Valneva intends to test its experimental Shigella vaccine in nearly 110 infants. Results from this study are expected later this year.
ANIPPositive Net Change CTMXPositive Net Change ETNBPositive Net Change VALNPositive Net Change
biotechs medical
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On
by Urmimala Biswas
Investors looking to maintain exposure to healthcare can invest in large-cap U.S.-based companies like UHS, BMRN and ABT.
ABTPositive Net Change BMRNPositive Net Change UHSPositive Net Change
biotechs medical medical-devices pharmaceuticals
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
by Ekta Bagri
PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.
BMYPositive Net Change AMGNPositive Net Change SRPTPositive Net Change PCRXPositive Net Change EWTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo
by Zacks Equity Research
Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the first-line setting.
BMYPositive Net Change FOLDPositive Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
by Zacks Equity Research
Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.
FOLDPositive Net Change ANIPPositive Net Change NCNAPositive Net Change RLYBPositive Net Change
biotechs
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
by Zacks Equity Research
Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.
DVAXPositive Net Change BAYRYPositive Net Change ADMAPositive Net Change RXRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Sundeep Ganoria
We advise investors to use the price dip in JAZZ stock as a buying opportunity despite the dynamic shifts in the regulatory landscape.
JAZZPositive Net Change EBSPositive Net Change CMRXPositive Net Change
biotechs cannabis medical pharmaceuticals
PCRX Stock Soars on Exparel Patent Settlement With Generic Players
by Zacks Equity Research
Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.
DVAXPositive Net Change BAYRYPositive Net Change PCRXPositive Net Change ADMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study
by Zacks Equity Research
Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.
DVAXPositive Net Change BAYRYPositive Net Change ADMAPositive Net Change RYTMPositive Net Change
biotechnology biotechs medical pharmaceuticals
Viatris to Pay $335 Million for Settlement of Opioid-Related Claims
by Zacks Equity Research
VTRS has reached an agreement of $335 million to resolve opioid-related claims by states, local governments, and tribes against it and certain of its subsidiaries.
PFEPositive Net Change BMRNPositive Net Change ADMAPositive Net Change VTRSPositive Net Change
biotechnology biotechs medical pharmaceuticals
VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe
by Zacks Equity Research
With the latest approval, Vertex's Kaftrio is now eligible to treat about 4,000 people living in the EU with rare mutations of cystic fibrosis.
VRTXPositive Net Change MRNAPositive Net Change ANIPPositive Net Change ETNBPositive Net Change
biotechs medical messenger-rna pharmaceuticals
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
by Zacks Equity Research
The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate.
ANIPPositive Net Change CTMXPositive Net Change ALLONegative Net Change ETNBPositive Net Change
biotechs crispr medical pharmaceuticals
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
GILDPositive Net Change BMRNPositive Net Change FOLDPositive Net Change ADMAPositive Net Change KRYSPositive Net Change
biotechnology biotechs medical pharmaceuticals
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
by Zacks Equity Research
Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.
BAYRYPositive Net Change CYTKPositive Net Change ADMAPositive Net Change EWTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues
by Zacks Equity Research
bioAffinity witnesses record 2024 revenues, driven by CyPath Lung adoption, Medicare coverage and strategic expansion across healthcare networks.
BIAFNegative Net Change
biotechnology biotechs earnings medical